Biomarker Expansion Recent launch of intracellular NAD test using dried blood spots presents an opportunity to cross-sell companion biomarker assays, lab services, and data analytics tools to deepen customer engagement with precision health monitoring.

Data-Driven Offerings Focus on data-driven well-being suggests potential for selling analytics platforms, dashboards, and subscription services that integrate test results with personal health data, appealing to wellness-focused customers and potential employers offering health programs.

Affordability & Accessibility DBS-based testing can lower sample collection barriers; sales could target direct-to-consumer kits, clinician partnerships, and concierge lab services to expand reach and drive higher test volumes.

Growth-Stage Synergies Comparable-market revenue signals show opportunity to position Jinfiniti as a nimble biotech partner for mid-size clinics and specialty labs seeking scalable biomarker tests and rapid deployment.

Strategic Partnerships Leverage existing tech stack and digital marketing footprint to propose white-label software, integration with CRM/marketing automation, and referral networks to accelerate channel partnerships and add recurring revenue.